A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma

Bone

Volumn 29, Issue 4, 2001, Pages 393-402

  John, M R ^a,c   Wickert, H ^a   Zaar, K ^b   Jonsson, K B ^c   Grauer, A ^a   Ruppersberger, P ^d   Schmidt Gayk, H ^d   Murer, H ^e   Ziegler, R ^a   Blind, E ^f  

^a Sity of Heidelberg ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Laboratory Group   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Fibroblast growth factor 23 (FGF 23); Malignant schwannoma; Oncogenic osteomalacia; PHEX; Phosphate

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; METALLOPROTEINASE; PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CANCER CELL CULTURE; CASE REPORT; CELL HYBRIDIZATION; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MALIGNANT NEURILEMOMA; MUTATION; NEUROSECRETION; NONHUMAN; ONCOGENIC OSTEOMALACIA; OPOSSUM; PARANEOPLASTIC SYNDROME; PHOSPHATE TRANSPORT; SCHWANN CELL; VITAMIN D RESISTANT RICKETS;

FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEURILEMMOMA; NEUROENDOCRINE TUMORS; OSTEOMALACIA; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0034809953     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(01)00586-5     Document Type: Article

References (43)

1. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma
2. Aberrant regulation of ras proteins in malignant tumor cells from type 1 neurofibromatosis patients
3. Oncogenic osteomalacia induced by schwannoma in a patient with neurofibromatosis
4. Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy
5. Brief report: Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia
6. Hypophosphatemia induced in mice by transplantation of a tumor-derived cell line from a patient with oncogenic rickets
7. Tumor-induced osteomalacia
8. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
9. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13
10. Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets
11. Immunochemiluminometric assay with two monoclonal antibodies against the N-terminal sequence of human parathyroid hormone
12. The intermediate filament complement of the spectrum of nerve sheath neoplasms
13. Expression and cloning of the human X-linked hypophosphatemia gene cDNA
14. Vitamin-D-resistant osteomalacia
15. Inhibtition of renal cell phosphate uptake by PTHrP analogs lacking the N-terminus
16. Gene expression profiles of mesenchymal tumors associated with oncogenic osteomalcia
17. Signaling properties of the alternate human PTH receptor (PTH2 receptor) in transfected cells
18. Phosphatonin - A new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia)
19. Tumor-induced osteomalacia and the regulation of phosphate homeostasis
20. Inhibitors of renal epithelial phosphate transport in tumor-induced osteomalacia and uremia
21. Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse
22. Bone scan in tumor-induced osteomalacia
23. Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity
24. Oncogenic osteomalacia
25. Osteomalacia with Looser's nodes (milkman's syndrome) due to a raised resistance to vitamin D acquired about the age 15 years
26. Cytogenetic characterization of peripheral nerve sheath tumours: A report of the CHAMP study group
27. Hemangiopericytoma-induced osteomalacia: Tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity
28. Characteristics of tumor cell bioactivity in oncogenic osteomalacia
29. Further characterization of the phosphate transport regulating factor in oncogenic osteomalacia and mutation analysis of the PHEX gene in tumor cell DNA
30. Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: Evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia
31. Cloning of human PEX cDNA from tumors causing hypophosphatemic osteomalacia
32. +/Pi cotransporters
33. Multiple cytogenetic aberrations in neurofibrosarcomas complicating neurofibromatosis
34. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia
35. Parathyroid hormone-like bioactivity in tumours from patients with oncogenic osteomalacia
36. A neuroendocrine cause of oncogenic osteomalacia
37. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia
38. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets
39. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
40. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting
41. Oncogenic osteomalacia: Evidence for a humoral phosphaturic factor
42. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain